Baseline Characteristics of Patients From the Study Population by Clinical Trial
Leukemia, Cancer
GROUP B, LEUKEMIA, CANCER
Abbreviations: CALGB, Cancer and Leukemia Group B 40601 trial; ET, endocrine therapy; HL, trastuzumab plus lapatinib; TH, weekly paclitaxel plus trastuzumab; THL, TH plus lapatinib; TL, weekly paclitaxel plus lapatinib.Statistical differences were assessed with the Wilcoxon rank sum test (for age) and the Pearson χIn the CALGB 40601 trial, the median TIL count was 20% (IQR, 13.1%-45%) (eFigure 2A in the 